Search
Now showing items 1-4 of 4
A novel polymorphism in ABCB1 gene, CYP2B6*6 and sex predict single-dose efavirenz population pharmacokinetics in Ugandans
(Wiley-Blackwell, 2009)
AIMS
Efavirenz exhibits pharmacokinetic variability causing varied clinical response. The aim
was to develop an integrated population pharmacokinetic/pharmacogenetic model and
investigate the impact of genetic variations, ...
In silico prediction of efavirenz and rifampicin drug–drug interaction considering weight and CYP2B6 phenotype
(The British Pharmacological Society, 2010)
AIMS
This study aimed to test whether a pharmacokinetic simulation model
could extrapolate nonclinical drug data to predict human efavirenz
exposure after single and continuous dosing as well as the effects of
concomitant ...
HIV/AIDS patients display lower relative bioavailability of Efavirenz than healthy subjects
(Adis Data Information BV., 2011)
Background: Pharmacokinetic studies of antiretroviral drugs are often conducted in adult healthy subjects, and the results are extrapolated to HIV/AIDS patients. HIV/AIDS, however, is known to cause morphological and ...
Development and validation of an HPLC-UV method for the simultaneous determination of Efavirenz and Dolutegravir in human plasma
(Makerere University, 2022-12)
Background: Although HIV/AIDS possess a challenge, global efforts have been mounted to address the epidemic. These include the massive role out of anti-retroviral therapy (ART) globally. To date either efavirenz or ...